XML 32 R15.htm IDEA: XBRL DOCUMENT
v3.24.0.1

SHARE-BASED COMPENSATION | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
SHARE-BASED COMPENSATION | SHARE-BASED COMPENSATION We provide for various forms of share-based compensation awards to our employees and non-employee directors. Our share-based compensation plans allow for the issuance of a mix of stock options, restricted stock, stock appreciation rights, employee stock purchase rights, and other stock unit awards. With the exception of stock options, the fair value of our awards is equal to the closing stock price of IDEXX common stock on the date of grant. We calculate the fair value of our stock option awards using the Black-Scholes-Merton option-pricing model. For stock options, restricted stock units (“RSUs”), and deferred stock units (“DSUs”), share-based compensation expense is estimated based on awards ultimately expected to vest, reduced for estimated forfeitures, on a straight-line basis over the requisite service period of the award. For performance-based restricted stock units (“PBRSUs”), share-based compensation expense is estimated based on awards ultimately expected to vest, reduced for estimated forfeitures, on a graded vesting methodology over the requisite service period. Stock options permit a holder to buy IDEXX stock upon vesting at the stock option exercise price set on the day of grant. An RSU is an agreement to issue shares of IDEXX stock at the time of vesting. A PBRSU is an agreement to issue shares of IDEXX stock at the time of vesting upon successful completion of certain performance goals. DSUs are granted under our Executive Deferred Compensation Plan (the “Executive Plan”) and non-employee Director Deferred Compensation Plan (the “Director Plan”). DSUs may or may not have vesting conditions depending on the plan under which they are issued. We did not issue any restricted stock or stock appreciation rights during the years ended December 31, 2023, 2022, and 2021, nor were any restricted stock or stock appreciation rights outstanding as of those years then ended. We primarily issue shares of common stock to satisfy stock option exercises and employee stock purchase rights and to settle RSUs, PBRSUs, and DSUs. We issue shares of treasury stock to settle certain RSUs and upon the exercise of certain stock options, which were not material for the years ended December 31, 2023, 2022, and 2021. The number of shares of common stock and treasury stock issued are equivalent to the number of awards exercised or settled. With the exception of employee stock purchase rights, equity awards are issued to employees and non-employee di rectors under the 2018 Stock Incentive Plan (the “2018 Stock Plan”). Our Board of Directors has authorized the issuance of 7.5 million shar es of our common stock under the 2018 Stock Plan. Any shares that are subject to awards of stock options or stock appreciation rights will be counted against the share limit as one share for every share granted. Any shares that are issued other than stock options and stock appreciation rights will be counted against the share limit as 2.4 shares for every share granted. If any shares issued under our prior plans are forfeited, settled for cash, or expire, these shares, to the extent of such forfeiture, cash settlement, or expiration, will again be available for issuance under the 2018 Stock Plan. As of December 31, 2023, there were approximately 6.1 million remaining shares available for issuance under the 2018 Stock Plan. Share-Based Compensation Share-based compensation costs are classified in the consolidated financial statements consistent with the classification of cash compensation paid to the employees receiving such share-based compensation. The following is a summary of share-based compensation costs and related tax benefits recorded in our consolidated statements of income:
(in thousands) |  | For the Years Ended December 31,
|  | 2023 |  | 2022 |  | 2021
Share-based compensation expense included in cost of revenue |  | $ | 5,643 |  |  | $ | 4,638 |  |  | $ | 4,044 |
Share-based compensation expense included in operating expenses |  | 54,096 |  |  | 45,132 |  |  | 33,711 |
Total share-based compensation expense included in consolidated statements of income |  | 59,739 |  |  | 49,770 |  |  | 37,755 |
Income tax benefit resulting from share-based compensation expense |  | (5,487) |  |  | (4,658) |  |  | (4,734) |
Net share-based compensation expense included in consolidated statements of income, excluding tax benefit from settlement of share-based awards |  | 54,252 |  |  | 45,112 |  |  | 33,021 |
Income tax benefit resulting from settlement of share-based awards |  | (13,703) |  |  | (12,522) |  |  | (32,474) |
Net expense related to share-based compensation arrangements included in consolidated statements of income |  | $ | 40,549 |  |  | $ | 32,590 |  |  | $ | 547 |
There were no material modifications to the terms of outstanding options, RSUs, PBRSUs, or DSUs during the years ended December 31, 2023, 2022, or 2021. Share-based compensation expense is reduced for an estimate of the number of awards that are expected to be forfeited. We use historical data and other factors to estimate expected employee terminations and to evaluate whether particular groups of employees have significantly different forfeiture expectations. Our share-based awards granted in certain years include a retirement provision for all employees based on age and length of service. These grants are subject to accelerated expensing if the holder meets the retirement definition set forth in the applicable equity and incentive plan document. The total unrecognized compensation expense, net of estimated forfeitures, for unvested share-based compensation awards at December 31, 2023, was $60.2 million, which will be recognized over a weighted average period of approximately 1.3 years. Stock Options Prior to December 4, 2019, all options granted to employees primarily vest ratably over five years on each anniversary of the date of grant. Options granted to non-employee directors vest fully on the earlier of the first anniversary of grant or date of the following annual meeting. Employee grants after December 4, 2019 vest ratably over four years. Vesting of option awards issued is conditional upon continuous service, unless the employee retires under the retirement provision, for grants issued in 2018, 2019, 2022, and 2023, for which they will vest for two additional years following the retirement date. Options granted after May 8, 2013 have a contractual term of ten years. Upon any change in control of the company, 25% of the unvested stock options then outstanding will vest and become exercisable. However, if the acquiring entity does not assume outstanding options, then all options will vest immediately prior to the change in control. We use the Black-Scholes-Merton option-pricing model to determine the fair value of options granted. Option-pricing models require the input of highly subjective assumptions, particularly for the expected stock price volatility and the expected term of options. Changes in the subjective input assumptions can affect the fair value estimate. Our expected stock price volatility assumptions are based on the historical volatility of our stock over periods that are similar to the expected terms of grants and other relevant factors. We derive the expected term based on historical experience and other relevant factors concerning expected employee behavior with regard to option exercise. The risk-free interest rate is based on U.S. Treasury yields for a maturity approximating the expected term calculated at the date of grant. We have never paid cash dividends on our common stock and we have no intention to pay a dividend at this time; therefore, we assume that no dividends will be paid over the expected terms of option awards. We determine the assumptions used in the valuation of option awards as of the date of grant. Differences in the expected stock price volatility, expected term, or risk-free interest rate may necessitate distinct valuation assumptions at those grant dates. As such, we may use different assumptions for options granted throughout the year. The weighted averages of the valuation assumptions used to determine the fair value of each option award on the date of grant and the weighted average estimated fair values were as follows:
|  | For the Years Ended December 31,
|  | 2023 |  | 2022 |  | 2021
Expected stock price volatility |  | 32 | % |  | 30 | % |  | 30 | %
Expected term, in years |  | 6.7 |  | 6.4 |  | 6.2
Risk-free interest rate |  | 3.7 | % |  | 2.1 | % |  | 0.7 | %
Weighted average fair value of options granted |  | $ | 201.48 |  |  | $ | 166.30 |  |  | $ | 169.15 |
A summary of the status of options granted under our share-based compensation plans at December 31, 2023, and changes during the year then ended, are presented in the table below:
|  | Number of Options (000) |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value ($000)
Outstanding as of December 31, 2022 |  | 1,701 |  | $ | 219.90 |  |  |  |  |
Granted |  | 142 |  | $ | 503.50 |  |  |  |  |
Exercised |  | (215) |  | $ | 147.69 |  |  |  |  |
Forfeited |  | (26) |  | $ | 432.43 |  |  |  |  |
Expired |  | (6) |  | $ | 545.55 |  |  |  |  |
Outstanding as of December 31, 2023 |  | 1,596 |  | $ | 250.14 |  |  | 4.8 |  | $ | 487,487 |
Fully vested as of December 31, 2023 |  | 1,209 |  | $ | 186.45 |  |  | 3.9 |  | $ | 446,109 |
Fully vested and expected to vest as of December 31, 2023 (1) |  | 1,581 |  | $ | 247.85 |  |  | 4.8 |  | $ | 486,636 |
(1) Includes options that are vested as of December 31, 2023, and outstanding options that are expected to vest in the future, net of estimated forfeitures.
The total fair value of options vested were $22.5 million, $20.4 million, and $17.3 million during the years ended December 31, 2023, 2022, and 2021, respectively. Intrinsic value of stock options exercised represents the amount by which the market price of the common stock exceeded the exercise price before applicable income taxes. The total intrinsic values of stock options exercised were $75.5 million, $54.6 million, and $147.9 million during the years ended December 31, 2023, 2022, and 2021, respectively. Restricted Stock Units Prior to December 4, 2019, the majority of RSUs, including our PBRSUs, granted to employees vest ratably over five years on each anniversary of the date of grant. The majority of employee grants after December 4, 2019, vest ratably over four years. A minority of some employee grants cliff-vest three years from date of grant. PBRSUs granted to employees vest based on meeting performance goals set on the day of grant. Vesting as it relates to RSUs and PBRSUs issued is conditional upon continuous service, unless the employee retires under the retirement provision, for grants issued in 2018, 2019, 2022, and 2023, for which they will vest for two additional years following the retirement date. Upon any change in control of the company, 25% of the unvested RSUs and PBRSUs then outstanding will vest, provided, however, that if the acquiring entity does not assume the RSUs and PBRSUs, then all such units will vest immediately prior to the change in control. At time of grant, we assume all PBRSUs will meet performance goals to vest. RSUs granted to non-employee directors vest fully on the first anniversary of the date of grant. A summary of the status of RSUs and PBRSUs granted under our share-based compensation plans at December 31, 2023, and changes during the period then ended, are presented in the table below:
|  | Number of Units (000) |  | Weighted Average Grant-Date Fair Value
Nonvested as of December 31, 2022 |  | 148 |  | $ | 391.55 |
Granted |  | 63 |  |
Vested |  | (62) |  |
Forfeited |  | (8) |  |
Nonvested as of December 31, 2023 |  | 141 |  | $ | 459.11 |
Expected to vest as of December 31, 2023 (1) |  | 134 |  | $ | 457.51 |
(1) Outstanding units that are expected to vest in the future, net of estimated forfeitures.
The total fair values of RSUs and PBRSUs vested were $31.1 million, $32.9 million, and $46.1 million during the years ended December 31, 2023, 2022, and 2021, respectively. The aggregate intrinsic value of nonvested RSUs and PBRSUs as of December 31, 2023, which is equal to the fair value of IDEXX’s common stock as of December 31, 2023, multiplied by the number of nonvested units as of December 31, 2023, was $78.0 million. Deferred Stock Units Under our Director Plan, non-employee directors may defer a portion of their cash fees in the form of vested DSUs. Prior to 2014, certain members of our management could elect to defer a portion of their cash compensation in the form of vested deferred stock units under our Executive Plan. Each DSU represents the right to receive one unissued share of our common stock. These recipients receive a number of DSUs equal to the amount of cash fees or compensation deferred divided by the closing sale price of the common stock on the date of deferral. Also under the Director Plan, non-employee directors are awarded annual grants of either RSUs or DSUs that vest fully on the earlier of the first anniversary of grant or date of the following annual meeting. Vesting for these annual RSU and DSU grants is conditional upon continuous service. Vested DSUs are distributed as shares of common stock on the distribution date elected by the participant and pursuant to the terms of the Director or Executive Plan, as applicable. There were approximately 59,000 and 58,000 vested DSUs outstanding under our share-based compensation plans as of December 31, 2023 and 2022, respectively. During 2023, approximately 300 DSUs were distributed as shares of common stock. Unvested DSUs as of December 31, 2023 and 2022, were not material. Employee Stock Purchase Rights Employee stock purchase rights are issued under the 1997 Employee Stock Purchase Plan, under which we reserved and may issue up to an aggregate of 4.7 million shares of common stock in periodic offerings. Under this plan, stock is sold to employees at a 15% discount off the closing price of the stock on the last day of each quarter. The dollar value of this discount is equal to the fair value of purchase rights recognized as share-based compensation. We issued approximately 36,300, 44,600, and 29,500 shares of common stock in connection with the Employee Stock Purchase Plan during the years ended December 31, 2023, 2022, and 2021, respectively. As of December 31, 2023, there were approximately 1.0 million remaining shares available for issuance under the 1997 Employee Stock Purchase Plan.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration